# 2026-20085: FDA Seeks Comments on Medical Device Improvement Program Paperwork

2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-10-01, effective Submit written comments (including recommendations) on the collection of information by November 2, 2026.; PRIA reads it as touching household money (as of 2026-10-08).

- Canonical: https://policyrisk.com/federal-register/2026-20085
- As of: 2026-10-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20085
- Title: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 62528
- Published: 2026-10-01
- Effective: Submit written comments (including recommendations) on the collection of information by November 2, 2026.
- Comments close: 2026-11-02
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-08

## In one line

FDA Seeks Comments on Medical Device Improvement Program Paperwork

## Summary

The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.

## Abstract

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

## Effects PRIA read

- Voluntary program aims to improve device safety: benefit, low. The FDA’s Voluntary Improvement Program (VIP) supports third-party appraisals to help medical device makers improve product quality and produce safer devices. The notice says this supports better products and safer devices without adding extra costs or deadlines for companies and is facilitated by…
- Program limited to eligible CDRH manufacturers: benefit, low. Only eligible manufacturers of medical devices regulated by the Center for Devices and Radiological Health (CDRH) whose marketing applications are reviewed under the Federal Food, Drug, and Cosmetic Act—specifically sections 510(k), 513, 515, and 520—may participate in the VIP.
- Reporting time burden on third-party appraisers: cost, medium. FDA estimates the reporting burden for the VIP as: 300 site manufacturer application responses totaling 24 hours (0.08 hours each), 4 aggregate data reports totaling 32 hours (8 hours each), and 300 summaries of site appraisals totaling 6,000 hours (20 hours each), for a combined annual total of 6,…
- FDA will not publish appraisal benchmark data or require standard forms: cost, low. FDA states it does not plan to make de-identified, aggregated benchmark data from VIP appraisals publicly available and will not require a common application form, standardized delta reports, or pre-populated fields from FDA databases for submissions. VIP remains a voluntary program and uses indivi…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20085 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/01/2026-20085/agency-information-collection-activities-submission-for-office-of-management-and-budget-review)
- [2026-20085 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-01/pdf/2026-20085.pdf)

## Related
- [Previous: 2026-20083, Notice of Lodging of Proposed Consent Decree Under the Clean Air Act](https://policyrisk.com/federal-register/2026-20083)
- [Next: 2026-20086, Privacy Act of 1974; System of Records](https://policyrisk.com/federal-register/2026-20086)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20085 (as of 2026-10-08).
